-> en Français <-

1. Carpentier AF, Chen L, Maltonti F, Delattre JY. (1999). Oligodesoxynucleotides containing CpG motifs can cure neuroblastoma in mice. Cancer Research, 59, 5429-5432.

Link to the document...

(02-11-2011)

2. Carpentier AF, Xie J, Mokthari K, Delattre JY. (2000). Successful treatment of intracranial gliomas in rats with oligodeosynucleotides containing CpG motifs. Clinical Cancer Research, 6: 2469-73.

Link to the document...

(02-11-2011)

3. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. (2001). Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res; 7: 3540-3.

Link to the document...

(02-11-2011)

4. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L. (2004). Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 172:2137-46.

Link to the document...

(02-11-2011)

5. Meng Y, Carpentier AF; Chen L; Boisserie G; Simon JM; Mazeron JJ; Delattre JY. (2005). Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer;116: 992-7

Link to the document...

(02-11-2011)

6. Carpentier A, Zohar S, Capelle L, Behin A, Tibi A, Laigle-Donadey F, Puybasset L, Sanson M, Van Effenterre R; Delattre JY, Carpentier AF. (2006). Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology, 8: 60-6.

Link to the document...

(02-11-2011)

7. Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol. 2006;18: 631-6.

Link to the document...

(02-11-2011)

8. Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF. Expression of TLR9 within human glioblastoma. J Neurooncol. 2008; 88:19-25.

Link to the document...

(02-11-2011)

9. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother. 2008; 57: 1291-300.

Link to the document...

(02-11-2011)

10. Chennaoui M, Drogou C, Carpentier AF, Guezennec CY, Gomez-Merino D. Cytokine content in lymphoid and white adipose tissues after repeated CpG oligodeoxynucleotide administration in trained rats. Vaccine. 2010; 28: 1814-8.

Link to the document...

(02-11-2011)

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

View / Download document (143 ko)...

(09-06-2010)

Successful combination of local CpG-ODN and radiotherapy in malignant glioma

View / Download document (120 ko)...

(09-06-2010)

Phase I trial of a CpG Oligodeoxynucleotide for patients with recurrent glioblastoma

View / Download document (1489 ko)...

(14-11-2007)

CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease

View / Download document (172 ko)...

(14-11-2007)

CpG oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma

View / Download document (698 ko)...

(14-11-2007)

Oligodeoxynucleotides Containing CpG Motifs Can Induce Rejection of a Neuroblastoma in Mice

Cancer Res 1999 59: 5429-5432

Link to the document...

(14-11-2007)

Implication of Macrophages in Tumor Rejection Induced by CpG-oligodeoxynucleotides Without Antigen

Clin Cancer Res 2001 7: 3540

Link to the document...

(14-11-2007)

Successful Treatment of Intracranial Gliomas in Rat by Oligodeoxynucleotides Containing CpG Motifs

Clin Cancer Res 2000 6: 2469

Link to the document...

(14-11-2007)

Home \ Publications   
 

Welcome to Oligovax !
All the Oligovax team welcomes you to our website...


Home
| Company | Scientific Background | Clinical Developments | Intellectual Property | Contact

English | Français